Series of 10 Reports from the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida 2010
The 52nd Annual Meeting of the American Society for Hematology (ASH), held on December 4-7, 2010 in Orlando, FL, provided a number of presentations of results of clinical research focusing on improving outcomes in patients with iron overload. Patients with chronic medical conditions that cause anaemia need to receive frequent transfusions of packed red blood cells. Unfortunately, these transfusions cause iron overload that damages major organs including the heart and liver. Management of the iron burden constitutes an important aspect of the management of these patients. Several iron chelation agents are approved throughout the world for treating iron overload, but further research is needed in a number of important areas so that clinicians may improve patient outcomes.
Target AudienceThis activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
- Evaluate clinical trial data on haematologic responses in patients with MDS receiving deferasirox therapy for transfusional iron overload in order to determine optimal treatment for transfusional iron overload in these patients.
- Evaluate data on the effects of deferasirox on hepatic fibrosis in patients with Î²-thalassaemia and hepatic transfusional iron overload in order to improve management of hepatic complications.
- Compare findings on the efficacy of different iron chelation therapies for reducing myocardial iron burden to guide decisions for optimal iron management in patients with thalassaemia major.
- Evaluate efficacy and safety findings for patients with sickle cell disease (SCD) receiving long-term (>4 years) therapy with deferasirox in order to determine optimal treatment for patients with SCD and iron overload.